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The kinetics of the postantibiotic effect (PAE) during one dosing interval of tobramycin against Staphylo-
coccus aureus and Pseudomonas aeruginosa was investigated. We determined the PAE at different time points
during this dosing interval of 12 h in an in vitro pharmacokinetic model simulating human pharmacokinetics
in which the half-life of tobramycin was adjusted to 2.4 6 0.2 h. Using an enzymatic method to inactivate
tobramycin, we determined PAEs in samples extracted from the model at 1, 5, 8, and 12 h, corresponding with
tobramycin concentrations of 20, 5, 2, and 1 times the MIC for the test organism. The PAE decreased
significantly from 2.5 h at 1 h to 0 h at 12 h. No change in MIC was observed for the strains during the
experiments. We conclude that the PAE decreases with decreasing tobramycin concentrations during a 12-h
dosing interval and completely disappears after the concentration has reached the MIC for the test organism.
On the basis of these observations, the emphasis that is placed on the PAE in discussions about the optimal
dosing interval in aminoglycoside therapy is questionable.
Three factors are relevant when determining an aminogly-
coside dosing schedule, i.e., the susceptibility of the bacterium
(MIC), the kinetics of antibacterial activity, and the postan-
tibiotic effect (PAE) (2). The PAE is usually determined after
1 or 2 h of exposure to antibiotics at four times the MIC
(43MIC) to 53MIC followed by immediate removal or inac-
tivation of the antibiotic. Partly on the basis of these data,
intermittent therapy of aminoglycosides with longer dosing
intervals, such as once- or twice-daily dosing, has been intro-
duced into clinical practice (7, 8, 16, 19) since the PAE sup-
posedly would prevent bacterial growth when drug concentra-
tions in serum and tissue fall below the MIC (1). However, the
PAE is determined in vitro after 1 or 2 h of exposure to fixed
antibiotic concentrations while in the clinical setting aminogly-
coside concentrations decline over time, with an elimination
half-life of several hours. It could well be that the PAE has
disappeared by the time the concentration falls below the MIC,
thus losing its clinical relevance.
In the present study, the PAE was determined during one
dosing interval of tobramycin in a pharmacokinetic model sim-
ulating human pharmacokinetics. The PAE was determined at
four time points during this dosing interval of 12 h to study the
kinetics of the PAE itself and to determine whether the PAE
is still present when the drug concentration falls below the
MIC for the infecting organism.
The strains used for this experiment were Staphylococcus
aureus ATCC 29213 and Pseudomonas aeruginosa ATCC
27853. The MIC of tobramycin (Eli Lilly and Company, Nieu-
wegein, The Netherlands) was 0.5 mg/liter for S. aureus and 0.5
mg/liter for P. aeruginosa, determined by both a standard ma-
crodilution method with Mueller-Hinton broth (MHB) supple-
mented with Ca21 (25 mg/liter) and Mg21 (12.5 mg/liter)
(Difco, Amsterdam, The Netherlands) and an agar dilution
method (15).
The model used was described previously in detail (14).
Briefly, a two-compartment model consisting of one central
compartment and four peripheral compartments consisting of
disposable dialyzer units (ST23; Baxter, Utrecht, The Nether-
lands) was used to expose the bacteria in the peripheral com-
partments to changing antibiotic concentrations, mimicking
human pharmacokinetics. A volume of 150 ml of a logarithmic-
phase culture of S. aureus or P. aeruginosa at a concentration of
approximately 107 CFU/ml was injected into the peripheral
compartments starting at 0 h, tobramycin was infused into the
central compartment for 1 h with an infuser (Braun, Melsun-
gen AG, Germany), providing a total dose of 15 mg/liter and
resulting in a peak concentration of approximately 10 mg/liter
at 1 h. The half-life of tobramycin was adjusted to approxi-
mately 2 h. To determine the tobramycin concentration by a
fluorescence polarization immunoassay using a TDxFLx device
(Abbott Diagnostic Division, Amstelveen, The Netherlands)
and colony counts, samples were taken at 0, 10, and 30 min and
1, 5, 8, and 12 h from both the central and peripheral com-
partments. To determine the killing rates for the two strains,
the samples were washed two times with cold saline, diluted
serially 10-fold in cold saline, and plated on tryptone soy agar
plates (Oxoid, Basingstoke, Hampshire, England) for colony
count determination. Control growth curves were also deter-
mined in the pharmacokinetic model.
To determine the PAE, samples were taken at 1, 5, 8, and 12
h, corresponding with estimated tobramycin concentrations of
203MIC (peak), 53MIC, 23MIC, and 13MIC (trough), re-
spectively. An enzymatic method for the removal of tobramy-
cin was used (5). Briefly, each 1-ml sample was added to 9 ml
of Mueller-Hinton broth at 378C. To this medium a tobramy-
cin-acetylating enzyme [AAC(3)-II] (12) and acetyl coenzyme
A were added, resulting in the inactivation of tobramycin
within 5 min. The PAE was defined according to Craig and
Gudmundsson (3) as follows: PAE 5 T 2 C, where T is the
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time required for the CFU count in the test culture to increase
1 log10 above the count immediately after drug removal and C
is the corresponding time for the controls. From the PAE
regrowth cultures, samples were taken at 0, 1, 2, 3, 4, and 6 h
and diluted serially in cold saline. Each dilution was plated on
tryptone soy agar and incubated overnight at 378C.
Control growth curves were determined in the pharmacoki-
netic model, which was treated as the test cultures were, only
without the addition of tobramycin. For the determination of
PAE control curves, samples were taken at 0, 1, 5, 8, and 12 h
and diluted in Mueller-Hinton broth at 378C until the inocu-
lum had the same starting value for CFU per milliliter as the
test strain did at the time, thus ruling out the possibility of an
inoculum effect. As a control, 1 ml of this inoculum was treated
as the test strains were by adding tobramycin-acetylating en-
zyme and acetyl coenzyme A. The experiment was repeated
four times in duplicate for each strain. MICs were determined
by a standard agar dilution method (15) for the strains isolated
from the samples at 1, 5, 8, and 12 h.
The SAS computer package (18) was used for statistical
analysis. The PAEs at four different time points were analyzed
by the Tukey-Kramer multiple-comparison test and the values
determined for regrowth during the killing curve were ana-
lyzed by repeated measurement and analysis of variance.
The mean concentrations 6 standard deviations for tobra-
mycin in the four experiments in the pharmacokinetic model
are shown in Table 1. The peak and trough concentrations as
well as the half-lives did not vary significantly between separate
experiments. The actual measured half-life 6 the standard
deviation was 2.4 6 0.2 h, which is slightly longer than the
adjusted half-life but is still within the range of half-lives found
for patients.
Killing and regrowth curves of S. aureus and P. aeruginosa
were determined at 1, 5, 8, and 12 h. A representative example
of a killing and a regrowth curve of both strains in the phar-
macokinetic model is shown in Fig. 1. The figure also shows an
example of a control growth curve and its regrowth curve,
which were determined separately. The regrowth which is seen
in the killing curve in the model is significant over time from 1
to 12 h (P 5 0.0022) for P. aeruginosa but not for S. aureus
during all experiments.
A summary of all PAEs determined at all time points is given
in Table 1. For both S. aureus and P. aeruginosa, the PAE after
a 1-hour exposure at a tobramycin concentration of 203MIC
was approximately 2.5 h. The PAEs determined at 12 h were
essentially 0 h. Thus, the PAE of tobramycin decreases rapidly
over time in concordance with the concentration-versus-MIC
ratio in this pharmacokinetic model. The MICs of tobramycin
for S. aureus and P. aeruginosa isolated from the samples at 1,
5, 8, and 12 h were 0.5 mg/liter. No genotypically resistant
strains were isolated during the experiments.
In this study, we describe the result that the PAE decreases
to 0 h during one dosing interval of tobramycin. PAEs deter-
mined at the peak concentration of about 10.6 mg/liter were
approximately 2.5 h for both S. aureus and P. aeruginosa,
slightly higher than those found in literature when determined
at 43MIC to 53MIC (3). The PAE at the peak concentration
is determined after an exposure of 1 h, but at a final concen-
tration of 203MIC. This could explain the slight difference
relative to the PAEs determined at 43MIC to 53MIC. During
the dosing interval, however, PAEs decreased to 0 h at 12 h,
i.e., when the antibiotic concentration is approximately the
MIC. Apparently, during a half-life of 2.4 h the bacteria are
able to recover more rapidly than the time it takes for the
concentration of tobramycin to decrease to the MIC for these
strains.
The PAEs determined during in vivo experiments in animal
models are produced in rodents with a short antibiotic half-life
(significantly shorter than that for humans) (3). But if the
half-life for the rodents is adjusted to that for humans by
FIG. 1. Representative curves for a control growth (F), control regrowth
(E), killing (), and killing regrowth () of S. aureus (a) and P. aeruginosa (b) as
determined during all experiments in the pharmacokinetic model are shown. For
these curves, samples for PAE measurement were taken at 8 h. PAE can be
determined as PAE5 T2 C, according to Craig and Gudmundsson (3) (see text
for details).









S. aureus P. aeruginosa
1 10.6 (1.1) 21.2 2.6 (1.8–3.3) 2.5 (1.9–3.1)
5 2.6 (0.4) 5.2 0.7 (0.2–1.2)c 0.9 (0.6–1.2)c
8 1.1 (0.2) 2.2 0.6 (0.1–1.0)c 1.5 (1.1–1.9)c
12 0.5 (0.1) 1.0 0.1 (20.1–0.3)c 20.3 (20.6–0.0)c
a Data are means of four separate experiments performed in duplicate. Values
in parentheses are standard deviations.
b Data are means of four separate experiments performed in duplicate. Values
in parentheses are 95% confidence intervals.
c Significant decrease compared with the PAE at 1 h.
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inducing renal impairment, the PAEs become even longer (4),
so the half-life cannot be used as an explanation for the de-
clining of the PAE in the in vitro model.
The PAE not only declines during a dosing interval but also
disappears after multiple antibiotic exposures (9, 11, 13, 17).
However, in previous studies (9, 11, 13, 17) the bacterial cul-
tures were repeatedly exposed to the same concentration of
antibiotic for short periods of time (2 h).
The killing curve of P. aeruginosa as determined in the
model (Fig. 1) shows a significant log-linear trend (P, 0.0001)
from 5 to 12 h. At the beginning of the dosing interval, bacteria
are killed rapidly, and this is followed by a lag phase induced by
tobramycin (from 1 to 5 h) during which the number of CFU
per milliliter does not change significantly in the model. Dur-
ing the ensuing period bacterial growth accelerates, leading to
a significant increase in CFU per milliliter from 5 to 12 h. This
could be due to regrowth of phenotypically resistant subpopu-
lations, since growth was observed at tobramycin concentra-
tions exceeding the MIC. After subculturing, we did not ob-
serve an emergence in genotypical resistance to tobramycin in
the organisms. The occurrence of phenotypically resistant sub-
populations cannot be excluded, as plating the samples on
tobramycin-containing agar was not performed. Thus, we can-
not confirm the observation of Karlowsky et al. (10) of a MIC
reversion time. The fact that regrowth of P. aeruginosa occurs
at tobramycin concentrations exceeding the MIC supports the
argument that keeping the tobramycin concentration above the
MIC is not the most important parameter of efficacy. The fast
initial killing caused by relatively high concentrations of ami-
noglycosides is possibly one of the most important factors
during therapy with these drugs. Another reason for this re-
growth phenomenon could be the difference in inoculum sizes
used for the MIC determination and for the PAE determina-
tion, 5 3 105 and 1 3 107 CFU/ml, respectively, since the use
of a larger inoculum could result in a higher MIC (the true
MIC). The MIC determined with an inoculum of 107 CFU/ml
was 1.0 mg/liter for both strains (data not shown). This how-
ever explains only the regrowth of P. aeruginosa observed after
8 h, when the tobramycin concentration decreases to ,1 mg/
liter.
In order to optimize the use of aminoglycoside antibiotics,
results of several studies investigating their pharmacodynamic
parameters predicting efficacy (1, 9, 10) and toxicological effect
(6) are being used. Dosing schedules have been determined by
matching the pharmacokinetic profile of a drug in normal
volunteers to the drug’s activity in vitro (20). The decrease of
the PAE to 0 h during a complete dosing interval might deflate
the importance which is given to the PAE in discussions about
the dosing interval in aminoglycoside therapy. The results of
this study do not argue against a change of thrice-daily to
once-daily dosing schedules, but they do question the role of
the PAE in its rationale. Thus, once-daily therapy can still be
favored on the basis of reduced toxicity (6) and higher peak
levels, producing a higher initial killing rate that may well be
clinically highly relevant (10).
In conclusion, the present study describes a significant de-
crease in PAE from 2.5 to 0 h during one dosing interval of
tobramycin. The important impact which is ascribed to the
PAE in discussions about the lengthening of the dosing inter-
val is therefore questioned.
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